Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: results of a randomised, double-blind, placebo-controlled study
Sodium oxybate (SMO) has been approved in Italy and Austria for the maintenance of abstinence in alcohol dependent (AD) patients. Although SMO is well tolerated in AD patients, cases of abuse and misuse have been reported outside the therapeutic setting. Here we report on a phase IIb double-blind, r...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
European neuropsychopharmacology
Year: 2021, Jahrgang: 52, Pages: 18-30 |
| ISSN: | 1873-7862 |
| DOI: | 10.1016/j.euroneuro.2021.06.003 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.euroneuro.2021.06.003 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0924977X21002522 
|
| Verfasserangaben: | Julien Guiraud, Giovanni Addolorato, Henri-Jean Aubin, Philippe Batel, Andrea de Bejczy, Fabio Caputo, Anna E. Goudriaan, Antoni Gual, Otto Lesch, Icro Maremmani, Pascal Perney, Roch Poulnais, Quentin Raffaillac, Bo Soderpalm, Rainer Spanagel, Henriette Walter, Wim van den Brink, for the SMO032 study group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1799761290 | ||
| 003 | DE-627 | ||
| 005 | 20240416193336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220419s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2021.06.003 |2 doi | |
| 035 | |a (DE-627)1799761290 | ||
| 035 | |a (DE-599)KXP1799761290 | ||
| 035 | |a (OCoLC)1341459083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Guiraud, Julien |e VerfasserIn |0 (DE-588)1255676922 |0 (DE-627)1799762424 |4 aut | |
| 245 | 1 | 0 | |a Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate |b results of a randomised, double-blind, placebo-controlled study |c Julien Guiraud, Giovanni Addolorato, Henri-Jean Aubin, Philippe Batel, Andrea de Bejczy, Fabio Caputo, Anna E. Goudriaan, Antoni Gual, Otto Lesch, Icro Maremmani, Pascal Perney, Roch Poulnais, Quentin Raffaillac, Bo Soderpalm, Rainer Spanagel, Henriette Walter, Wim van den Brink, for the SMO032 study group |
| 264 | 1 | |c 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.04.2022 | ||
| 520 | |a Sodium oxybate (SMO) has been approved in Italy and Austria for the maintenance of abstinence in alcohol dependent (AD) patients. Although SMO is well tolerated in AD patients, cases of abuse and misuse have been reported outside the therapeutic setting. Here we report on a phase IIb double-blind, randomized, placebo-controlled trial for the maintenance of abstinence in AD patients with a new abuse and misuse deterrent formulation of SMO. A total of 509 AD patients were randomized to 12 weeks of placebo or one of four SMO doses (0.75, 1.25, 1.75 or 2.25 g t.i.d.) followed by a one-week medication-free period. The primary endpoint was the percentage of days abstinent (PDA) at end of treatment. An unexpectedly high placebo response (mean 73%, median 92%) was observed. This probably compromised the demonstration of efficacy in the PDA, but several secondary endpoints showed statistically significant improvements. A post-hoc subgroup analysis based on baseline severity showed no improvements in the mild group, but statistically significant improvements in the severe group: PDA: mean difference +15%, Cohen's d = 0.42; abstinence: risk difference +18%, risk ratio = 2.22. No safety concerns were reported. Although the primary endpoint was not significant in the overall population, several secondary endpoints were significant in the intent-to-treat population and post-hoc results showed that treatment with SMO was associated with a significant improvement in severe AD patients which is consistent with previous findings. New trials are warranted that take baseline severity into consideration. | ||
| 650 | 4 | |a Alcohol dependence | |
| 650 | 4 | |a Alcohol use disorders | |
| 650 | 4 | |a GHB | |
| 650 | 4 | |a Maintenance of abstinence | |
| 650 | 4 | |a RCT | |
| 650 | 4 | |a Sodium oxybate | |
| 700 | 1 | |a Addolorato, Giovanni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aubin, Henri-Jean |e VerfasserIn |4 aut | |
| 700 | 1 | |a Batel, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Bejczy, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Caputo, Fabio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goudriaan, Anna E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gual, Antoni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lesch, Otto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maremmani, Icro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perney, Pascal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Poulnais, Roch |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raffaillac, Quentin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soderpalm, Bo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spanagel, Rainer |d 1961- |e VerfasserIn |0 (DE-588)112706312 |0 (DE-627)521941261 |0 (DE-576)289740002 |4 aut | |
| 700 | 1 | |a Walter, Henriette |e VerfasserIn |4 aut | |
| 700 | 1 | |a van den Brink, Wim |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology |d Amsterdam : Elsevier, 1990 |g 52(2021), Seite 18-30 |h Online-Ressource |w (DE-627)320594025 |w (DE-600)2019305-1 |w (DE-576)266224334 |x 1873-7862 |7 nnas |a Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate results of a randomised, double-blind, placebo-controlled study |
| 773 | 1 | 8 | |g volume:52 |g year:2021 |g pages:18-30 |g extent:13 |a Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate results of a randomised, double-blind, placebo-controlled study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.euroneuro.2021.06.003 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0924977X21002522 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220419 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 112706312 |a Spanagel, Rainer |m 112706312:Spanagel, Rainer |d 60000 |e 60000PS112706312 |k 0/60000/ |p 15 | ||
| 999 | |a KXP-PPN1799761290 |e 411887511X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"13 S."}],"id":{"eki":["1799761290"],"doi":["10.1016/j.euroneuro.2021.06.003"]},"note":["Gesehen am 28.04.2022"],"relHost":[{"title":[{"subtitle":"ENP ; the journal of the European College of Neuropsychopharmacology","title":"European neuropsychopharmacology","title_sort":"European neuropsychopharmacology"}],"part":{"pages":"18-30","extent":"13","volume":"52","text":"52(2021), Seite 18-30","year":"2021"},"language":["eng"],"pubHistory":["1.1990/91 -"],"disp":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate results of a randomised, double-blind, placebo-controlled studyEuropean neuropsychopharmacology","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1873-7862"],"zdb":["2019305-1"],"eki":["320594025"]},"note":["Gesehen am 31.01.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"ENP"}],"recId":"320594025","origin":[{"publisherPlace":"Amsterdam","dateIssuedKey":"1990","publisher":"Elsevier","dateIssuedDisp":"1990-"}]}],"recId":"1799761290","origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Julien","role":"aut","display":"Guiraud, Julien","family":"Guiraud"},{"family":"Addolorato","given":"Giovanni","role":"aut","display":"Addolorato, Giovanni"},{"family":"Aubin","role":"aut","given":"Henri-Jean","display":"Aubin, Henri-Jean"},{"family":"Batel","display":"Batel, Philippe","role":"aut","given":"Philippe"},{"family":"de Bejczy","given":"Andrea","role":"aut","display":"de Bejczy, Andrea"},{"family":"Caputo","given":"Fabio","role":"aut","display":"Caputo, Fabio"},{"role":"aut","given":"Anna E.","display":"Goudriaan, Anna E.","family":"Goudriaan"},{"family":"Gual","role":"aut","given":"Antoni","display":"Gual, Antoni"},{"display":"Lesch, Otto","given":"Otto","role":"aut","family":"Lesch"},{"display":"Maremmani, Icro","given":"Icro","role":"aut","family":"Maremmani"},{"family":"Perney","display":"Perney, Pascal","given":"Pascal","role":"aut"},{"display":"Poulnais, Roch","given":"Roch","role":"aut","family":"Poulnais"},{"display":"Raffaillac, Quentin","given":"Quentin","role":"aut","family":"Raffaillac"},{"family":"Soderpalm","given":"Bo","role":"aut","display":"Soderpalm, Bo"},{"family":"Spanagel","given":"Rainer","role":"aut","display":"Spanagel, Rainer"},{"family":"Walter","display":"Walter, Henriette","role":"aut","given":"Henriette"},{"family":"van den Brink","given":"Wim","role":"aut","display":"van den Brink, Wim"}],"name":{"displayForm":["Julien Guiraud, Giovanni Addolorato, Henri-Jean Aubin, Philippe Batel, Andrea de Bejczy, Fabio Caputo, Anna E. Goudriaan, Antoni Gual, Otto Lesch, Icro Maremmani, Pascal Perney, Roch Poulnais, Quentin Raffaillac, Bo Soderpalm, Rainer Spanagel, Henriette Walter, Wim van den Brink, for the SMO032 study group"]},"title":[{"title_sort":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate","subtitle":"results of a randomised, double-blind, placebo-controlled study","title":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate"}],"language":["eng"]} | ||
| SRT | |a GUIRAUDJULTREATINGAL2021 | ||